Clinical Trials

25 enrolled

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT06863259 2026-02-18

Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

28 enrolled

Burkitt Lymphoma, Recurrence

NCT05544019 2026-02-13

Study of SGR-1505 in Mature B-Cell Neoplasms

98 enrolled

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Pyloric Stenosis, Hypertrophic, Lymphoma, Primary Effusion

NCT04872790 2026-02-10

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

20 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT03666000 2026-02-02

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

135 enrolled

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04545762 2026-01-14

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

36 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06777979 2025-12-04

CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

30 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06080191 2025-12-02

Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL

24 enrolled

Burkitt Lymphoma

NCT06559189 2025-11-28

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

53 enrolled

Burkitt Lymphoma, Hematologic Diseases, Recurrence

NCT06507514 2025-11-21

Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL

4 enrolled

Burkitt Lymphoma

NCT07239323 2025-11-20

In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies

24 enrolled

LymphoidPlasma cell

Burkitt Lymphoma, Multiple Myeloma, Lymphoma, B-Cell

NCT04260022 2025-11-05

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

LymphoidMyeloidOther hematologic neoplasm

242 enrolled

Blast Crisis, Burkitt Lymphoma, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03595917 2025-11-04

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

LymphoidMyeloidOther hematologic neoplasm

40 enrolled

Burkitt Lymphoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05653271 2025-08-11

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

42 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT06340737 2025-08-07

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

148 enrolled

Burkitt Lymphoma, Leukemia, Leukemia, Hairy Cell, Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07106749 2025-08-06

CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies

12 enrolled

Burkitt Lymphoma, Lymphoma, Leukemia, Myeloid, Acute

NCT06927466 2025-05-22

A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

33 enrolled

Burkitt Lymphoma, Recurrence

NCT05418088 2025-05-16

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

54 enrolled